Boothbay Fund Management’s Viking Therapeutics VKTX Stock Holding History

Boothbay Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-119,600	Closed	-$3.17M	–	2195
2025 Q2	$3.17M	Buy	119,600 +21,500	+22%	+$566K	0.06%	398
2025 Q1	$2.37M	Buy	98,100 +65,400	+200%	+$2.07M	0.06%	390
2024 Q4	$1.32M	Sell	32,700 -257,400	-89%	-$14.7M	0.03%	561
2024 Q3	$18.4M	Buy	290,100 +42,600	+17%	+$2.5M	0.42%	27
2024 Q2	$13.1M	Buy	247,500 +232,600	+1,561%	+$15.2M	0.31%	44
2024 Q1	$1.22M	Buy	+14,900	New	+$663K	0.02%	686
2020 Q1	–	Sell	-281	Closed	-$225K	–	1072
2019 Q4	$225K	Buy	+281	New	+$2.05K	0.02%	674
2019 Q2	–	Sell	-604	Closed	-$600K	–	906
2019 Q1	$600K	Buy	+604	New	+$5.06K	0.06%	340
2018 Q4	–	Sell	-173	Closed	-$301K	–	911
2018 Q3	$301K	Sell	173 -142	-45%	-$1.69K	0.03%	505
2018 Q2	$299K	Buy	+315	New	+$2.1K	0.03%	475

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boothbay Fund Management's VKTX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 11,205 shares — an estimated $294K sold.

Boothbay Fund Management first reported a position in VKTX in Q4 2017 and held it in 18 quarters. The position peaked at $3.28M in Q2 2024. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Boothbay Fund Management reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 11,205 Viking Therapeutics shares in Q4 2025, an estimated $294K.
Boothbay Fund Management first reported a position in Viking Therapeutics in Q4 2017 and held it in 18 quarters.
Boothbay Fund Management's Viking Therapeutics position peaked at $3.28M in Q2 2024.
424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.